gene_symbol
FCGR3A
hgnc_id
HGNC:3619
binding_type
receptor ligand recognition
cytotoxicity
NO
cytotoxicity_type
INDIRECT
cytotoxicity_mechanism
Enoblituzumab binds B7-H3 on tumor/stromal cells, then its Fc engages CD16A on NK cells/macrophages to drive ADCC/ADCP against B7-H3–positive targets. CD16A-expressing cells act as effectors and are not targeted or killed by the drug.
enzyme_product
Off
epitope
Off
variant
Off
isoform
Off
hla_specific
Off
gated
Off
other_modifier
Fc-mediated engagement for ADCC (NK cells)
trial_id_tar_ref
drug_id_tar_ref
disease_id_tar_ref
nct_id_tar_ref
NCT06014255
disease_id_num_tar_ref
2738
drug_id_num_tar_ref
7289